US biotechnology firm Janus Biotherapeutics said it has partnered with Swiss drug major Roche (ROG: SIX) to develop a toll-like receptor (TLR) inhibitor with the potential to treat several autoimmune diseases. If successful, the deal also provides for Roche to acquire US-based Janus.
Under the terms of the agreement, Janus will receive an undisclosed upfront cash payment and R&D funding over a collaboration period.
TLRs are an important class of proteins that play a key role in the innate immune system. Strong scientific evidence links aberrant TLR activation and signalling with the development of autoimmune disorders. Janus will work exclusively with Roche on TLR research and development.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze